ArticleCancer journal (Sudbury, Mass.)
Novel approaches to enhance the specificity and safety of engineered T cells.
Article in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Bringing cell therapy to tumors: considerations for optimal CAR binder design.Antibody therapeutics · 2023Review
- Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.Molecular and cellular biochemistry · 2023Review
- When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies.Frontiers in oncology · 2022Review
- CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- Mechanistic modelling of tyrosine recombination reveals key parameters determining the performance of a CAR T cell switching circuit.Engineering biology · 2020Article
- Immunotherapy - Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites.Cureus · 2019Review
- Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy.ACS synthetic biology · 2019Article
- A long way to the battlefront: CAR T cell therapy against solid cancers.Journal of Cancer · 2019Review
- CAR-T cells: the long and winding road to solid tumors.Cell death & disease · 2018Review
- Article
- Quantitative Imaging Approaches to Study the CAR Immunological Synapse.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Review
- A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Journal of hematology & oncology · 2017Review
- The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.Current hematologic malignancy reports · 2016Review
- Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.Trends in pharmacological sciences · 2016Review
- CAR models: next-generation CAR modifications for enhanced T-cell function.Molecular therapy oncolytics · 2016Review
- CAR therapy: the CD19 paradigm.The Journal of clinical investigation · 2015Review
- Synthetic biology in cell-based cancer immunotherapy.Trends in biotechnology · 2015Review
- The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.American journal of translational research · 2015Article
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Science translational medicine · 2014Article
- Current advances in T-cell-based cancer immunotherapy.Immunotherapy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
T-cell therapies using engineered T cells show great promise for cancer immunotherapy, as illustrated by the CD19 paradigm. Much of the excitement about this approach, and second-generation CARs in particular, is due to the dramatic clinical results recently reported by a few centers, especially in acute lymphoblastic leukemia, and the applicability of this approach, in principle, to a wide range of cancers. Extending the use of CAR therapies to cancers other than B-cell malignancies will require selective tumor targeting with minimal or acceptable "on-target, off-tumor" effects. The identification of new CAR target antigens is thus one of the next big challenges to address. Recognizing the paucity of currently available tumor-specific targets, we have developed broadly applicable approaches to enhance the tumor selectivity and safety of engineered T cells. Here, we review 2 promising concepts. One is to improve tumor targeting based on combinatorial antigen recognition. The other uses receptors that provide antigen-specific inhibition, which we named iCARs, to divert T cells from the normal tissues one wants to protect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.